Search hospitals > New York > New York
Icahn School of Medicine at Mount Sinai
Claim this profileNew York, New York 10029
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Multiple Myeloma
Conducts research for Lymphoma
Conducts research for Diabetes
1544 reported clinical trials
156 medical researchers
Summary
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Tumors, Multiple Myeloma, Lymphoma, Diabetes and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,138 conditions. There are 156 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Thomas Marron, MD PhD, and Deborah Doroshow, MD, PhD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
FGFR3 positive
2Tumors
Global LeaderStage IV
Stage III
EGFR positive
Top PIs
Edward J. KimUniversity of California Davis Comprehensive Cancer Center1 year of reported clinical research
Studies Cancer
Studies Adenocarcinoma
30 reported clinical trials
68 drugs studied
Matthew Galsky, M.D.Mount Sinai Medical Center4 years of reported clinical research
Studies Bladder Cancer
Studies Cancer
15 reported clinical trials
28 drugs studied
Thomas Marron, MD PhDIcahn School of Medicine at Mount Sinai1 year of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
14 reported clinical trials
24 drugs studied
Deborah Doroshow, MD, PhDMount Sinai Hospital4 years of reported clinical research
Studies Tumors
Studies Solid Tumors
13 reported clinical trials
37 drugs studied
Clinical Trials running at Icahn School of Medicine at Mount Sinai
Breast Cancer
Crohn's Disease
Lymphoma
Bladder Cancer
Attention Deficit Hyperactivity Disorder (ADHD)
Ulcerative Colitis
Psoriasis
Non-Small Cell Lung Cancer
Follicular Lymphoma
Heart Failure
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Giredestrant + Everolimus
for Advanced or Metastatic Breast Cancer
This trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
Recruiting2 awards Phase 37 criteria
Ovarian Suppression Therapy
for Breast Cancer
This trial tests TOL2506, a treatment that stops ovaries from working, in premenopausal women and men with hormone-sensitive breast cancer. It aims to reduce hormone levels to slow down or stop cancer growth. TOL2506 is a treatment that stops ovaries from working, similar to other ovarian suppression methods.
Recruiting2 awards Phase 39 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Icahn School of Medicine at Mount Sinai?
Icahn School of Medicine at Mount Sinai is a medical facility located in New York, New York. This center is recognized for care of Cancer, Tumors, Multiple Myeloma, Lymphoma, Diabetes and other specialties. Icahn School of Medicine at Mount Sinai is involved with conducting 1,544 clinical trials across 1,138 conditions. There are 156 research doctors associated with this hospital, such as Edward J. Kim, Matthew Galsky, M.D., Thomas Marron, MD PhD, and Deborah Doroshow, MD, PhD.
Where is Icahn School of Medicine at Mount Sinai located?
The Icahn School of Medicine at Mount Sinai is situated in Manhattan, New York, nestled on the Upper East Side between Fifth and Madison Avenues, covering East 98th to 102nd Streets. Accessible by subway line number 6 and bus lines M1, M2, M3, M4, M96, M98, M101, M102, M103, M106. For comprehensive public transit details, visit the Metropolitan Transportation Authority (MTA) website.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance at Icahn School of Medicine at Mount Sinai:**
- **Department of Patient Financial Services:** For financial assistance applications and eligibility inquiries, contact (212) 731-3100 or visit One Gustave L. Levy Place, Box 6000, New York, New York 10029.
**Insurance Inquiries:**
- **Customer Service Billing Office:** For insurance and billing questions, call (212) 987-3100, Monday-Friday, 8 am – 6 pm.
- **Mount Sinai Doctors Faculty Practice:** Participates in most insurance plans, including Medicare. Verify acceptance and discuss requirements by contacting the physician's office or your insurance company directly.
What insurance does Icahn School of Medicine at Mount Sinai accept?
The Icahn School of Medicine at Mount Sinai, part of the Mount Sinai Health System, participates in numerous health plan networks. It's important to verify that both the hospital and the physicians involved in your care accept your insurance plan. For detailed information on physician insurance participation, use the "Find a Doctor" feature at www.mountsinai.org, and for hospital-specific insurance information, direct inquiries to the respective departments or visit the hospital's website.
What awards or recognition has Icahn School of Medicine at Mount Sinai received?
The Icahn School of Medicine at Mount Sinai has been awarded a five-year, $55.5 million Clinical and Translational Science Award by the National Center for Advancing Translational Sciences, part of the NIH. This funding supports ConduITS, the Institute for Translational Sciences at Mount Sinai, enhancing its role in the CTSA Program, which includes 63 nationwide sites. It will boost Mount Sinai's capabilities in translational research informatics, digital health, and data science, accelerating research translation into discoveries for improved health outcomes across diverse populations.